PATH
🇺🇸United States
Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
Phase 2
Not yet recruiting
- Conditions
- Poliomyelitis
- Interventions
- Biological: Novel Oral Polio Vaccine Type 2 (nOPV2)Biological: Placebo (Sterile Water)
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- PATH
- Target Recruit Count
- 675
- Registration Number
- NCT06895486
- Locations
- 🇵🇦
Cevaxin - 24 de Diciembre, Panama, Panama
🇵🇦Cevaxin - Ave. México, Panama, Panama
🇵🇦Cevaxin - Chorrera, Panama, Panama
Infant Malaria Vaccine Schedule Optimization
Phase 2
Not yet recruiting
- Conditions
- Malaria Vaccines
- Interventions
- Biological: R21 Matrix-M (R21/MM) Malaria VaccineBiological: PlaceboBiological: Hexavalent VaccineBiological: Rotavirus, Live Attenuated (Oral) VaccineBiological: Meningococcal A conjugate vaccine
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- PATH
- Target Recruit Count
- 1200
- Registration Number
- NCT06879327
- Locations
- 🇧🇫
Institut de Recherche en Science de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso
🇧🇫Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso
MaCRA Part B in Nigeria
Not Applicable
Withdrawn
- Conditions
- Malaria
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- PATH
- Target Recruit Count
- 350
- Registration Number
- NCT06805110
MaCRA Part B in Côte d'Ivoire
Not Applicable
Withdrawn
- Conditions
- Malaria
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- PATH
- Target Recruit Count
- 231
- Registration Number
- NCT06804902
- Locations
- 🇨🇮
Health facilities in selected districts, Cities In Selected Districts, Côte D'Ivoire
© Copyright 2025. All Rights Reserved by MedPath